AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
The call/put imbalance tells a clear story. For next Friday’s expirations, the strike leads with 14,535 open contracts—nearly double the nearest competitor. This suggests institutional players are hedging or scaling up for a post-holiday rally. Meanwhile, the put at 2,312 contracts shows some downside caution, but it’s dwarfed by call volume.
Block trades add another layer. The GOOG20250919C235 and GOOG20251003C250 options saw massive $1.1M+ trades in September and October 2025. These weren’t random buys—they were strategic bets on AI-driven growth and cloud expansion, which still underpin GOOG’s fundamentals. If the stock retests $314.01 (Bollinger Middle Band), these old block trades could reanimate as profit-taking triggers.
No Major News, But Technicals Tell the StoryThere’s no recent headline risk for GOOG—no earnings, no product delays, no regulatory drama. That’s both a blessing and a curse. Without news to anchor sentiment, the market defaults to technical levels. The 30-day support/resistance range (313.73–316.56) is now a battleground. If GOOG breaks above 316.17 (upper 30D resistance), the 320-strike calls become a self-fulfilling prophecy. But watch the 200D moving average at $164.29—if the stock ever freefalls below $301.46 (lower Bollinger Band), panic could set in.
Actionable Trades for TodayThe next 72 hours will test GOOG’s resolve. A close above $316.17 (30D resistance) could trigger a multi-day rally toward $325, fueled by call buyers and block-trade profit-taking. But don’t ignore the risks: the RSI isn’t screaming overbought yet (47.67), but the MACD histogram’s negative divergence warns of a possible consolidation phase. This isn’t a one-way bet—it’s a calculated dance between momentum and caution. Position yourself to capitalize on the breakout… but keep a seatbelt handy.

Focus on daily option trades

Dec.26 2025

Dec.26 2025

Dec.26 2025

Dec.26 2025

Dec.26 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet